

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A therapeutic composition comprising a glycoprotein preparation having improved complement-dependent cytotoxicity activity, said glycoprotein having an immunoglobulin CH2 domain and said CH2 domain having at least one N-linked oligosaccharide, wherein substantially all of the oligosaccharide is a G2 oligosaccharide and wherein the amount of said glycoprotein containing G1 and G0 oligosaccharide does not exceed 10% by weight of the preparation, and wherein the glycoprotein preparation has improved complement-dependent cytotoxicity activity compared to a preparation of that glycoprotein having heterogeneous oligosaccharide.

2. (Original) The composition of claim 1 wherein the glycoprotein is an antibody.

3. (Original) The composition of claim 2 wherein the antibody is a monoclonal antibody.

4. (Original) The composition of claim 3 wherein the antibody is an IgG.

5. (Original) The composition of claim 4 wherein the IgG is human IgG1.

6. (Original) The composition of claim 5 wherein the monoclonal antibody is selected from the group consisting of an anti-CD20 specific monoclonal antibody, an anti-HER2 specific monoclonal antibody, and anti-VEGF specific monoclonal antibody, and an anti-IgE specific monoclonal antibody.

7. (Withdrawn) The composition of claim 1 wherein the glycoprotein is an immunoadhesin.

8. (Withdrawn) The composition of claim 7 wherein the immunoadhesin is a tumor necrosis factor-immunoglobulin G1 chimera.

9. (Withdrawn) The composition of claim 1 wherein the glycoprotein is an antibody-immunoadhesin chimera.

10-24. (Canceled)

25. (Original) A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.

26. (Original) A pharmaceutical composition comprising the composition of claim 6 and a pharmaceutically acceptable carrier.

27. (Withdrawn) A pharmaceutical composition comprising the composition of claim 7 and a pharmaceutically acceptable carrier.

28. (Previously presented) An article of manufacture, comprising:  
a container;  
a label on said container; and  
the composition of claim 1 contained within said container.

29. (Original) The article of claim 28 wherein the label on the container indicates that the composition can be used for the treatment of cancer.